Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

Embodiments of the invention involve treating ophthalmology conditions by the topical or oral use of acetylcholinesterase inhibitors. By effectively reducing or eliminating the population of demodex mites in affected areas and areas where demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the ophthalmological afflictions than any previously described method. Embodiments of the invention are useful for treating ocular afflictions caused by demodex-induced inflammatory eye conditions, including meibomian gland dysfunction, conjunctivitis, keratoconjunctivitis, hyperemia, blepharitis and dry eye disease.

Embodiments of the invention involve treating ophthalmology conditions by the topical or oral use of acetylcholinesterase inhibitors. By effectively reducing or eliminating the population of demodex mites in affected areas and areas where demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the ophthalmological afflictions than any previously described method. Embodiments of the invention are useful for treating ocular afflictions caused by demodex-induced inflammatory eye conditions, including meibomian gland dysfunction, conjunctivitis, keratoconjunctivitis, hyperemia, blepharitis and dry eye disease.

A crosslinkable composition is useful for preparing a skin contact adhesive or a coating on a substrate. The crosslinkable composition includes (A) a polyurethane-polyorganosiloxane copolymer and (B) a curing catalyst. The skin contact adhesive prepared by crosslinking the crosslinkable composition is useful in applications such as adhesives for medical tapes, adhesives for wound dressings, adhesives for prosthetics, ostomy appliance adhesives, adhesives for medical monitoring appliances, adhesives for scar therapy treatments, adhesives for cosmetic patches, and transdermal drug delivery systems.

The present invention provides a novel substance that promotes expression of filaggrin gene involved in improvement of the moisture retention function of skin. The inventors of the present invention found that expression of filaggrin gene fluctuates rhythmically over a roughly 24 hour cycle, screened candidate substances based on the time at which expression reaches a maximum following addition of the candidate substance, and identified zanthoxylum extract, 3-(1′-piperidine)propionic acid, geranium oil, cypress oil, rose oil, galvanum oil, pepper oil, basil oil, methyl-o-toluate, methyl anthranilate and dimethyl anthranilate as filaggrin gene expression promoting agents.

The present invention provides a novel substance that promotes expression of filaggrin gene involved in improvement of the moisture retention function of skin. The inventors of the present invention found that expression of filaggrin gene fluctuates rhythmically over a roughly 24 hour cycle, screened candidate substances based on the time at which expression reaches a maximum following addition of the candidate substance, and identified zanthoxylum extract, 3-(1′-piperidine)propionic acid, geranium oil, cypress oil, rose oil, galvanum oil, pepper oil, basil oil, methyl-o-toluate, methyl anthranilate and dimethyl anthranilate as filaggrin gene expression promoting agents.

The present invention relates to a delivery contact lens device for delivering cargo molecules. The device comprises cargo molecules and a nanocomposite comprising hydrophilic polymer domains, hydrophobic polymer domains, aqueous pores, and charged boundary double layers, wherein at least 80% of the cargo molecule partitions in the charged boundary double layers formed at the interface of (i) aqueous pores and (ii) either hydrophobic polymer domains or hydrophilic polymer domains, the charged boundary double layers have a surface charge density of 0.005 to 0.5 Coulomb/meter.sup.2, and the aqueous pores including the cargo molecules have a low ionic strength of 0.1 to 100 mM, and osmolarity of 200-300 mM. The device retains the cargo molecules within the contact lens in a storage mode under a low ionic strength condition and releases the cargo molecules immediately after being placed in a tear environment with a higher ionic strength.

The present invention relates to a delivery contact lens device for delivering cargo molecules. The device comprises cargo molecules and a nanocomposite comprising hydrophilic polymer domains, hydrophobic polymer domains, aqueous pores, and charged boundary double layers, wherein at least 80% of the cargo molecule partitions in the charged boundary double layers formed at the interface of (i) aqueous pores and (ii) either hydrophobic polymer domains or hydrophilic polymer domains, the charged boundary double layers have a surface charge density of 0.005 to 0.5 Coulomb/meter.sup.2, and the aqueous pores including the cargo molecules have a low ionic strength of 0.1 to 100 mM, and osmolarity of 200-300 mM. The device retains the cargo molecules within the contact lens in a storage mode under a low ionic strength condition and releases the cargo molecules immediately after being placed in a tear environment with a higher ionic strength.

Ophthalmic compositions for administration to an eye including a mixture of an antiseptic and an anesthetic in therapeutically effective amounts are disclosed. The compositions are both anesthetic and antiseptic, and can be used in various ophthalmic procedures.